Risedronate sodium 2.5-hydrate

• Long experience in in-house commercial manufacturing
• Extensive portfolio of Bisphosphonates
• Technology not generating genotoxic impurities

Status	Commercial
Therapeutic cat.	Musculo-skeletal
Polymorphic form	Form A
CAS No.	329003-65-8
Injectable Form	Injectable
EU DMF readiness
CEP
JAPANESE DMF
KOREAN??DMF
CANADIAN??DMF
CADIFA
US DMF readiness

Drug description

Risedronate is used to treat osteoporosis caused by menopause, or steroid use. risedronate is for use when you have a high risk of bone fracture due to osteoporosis. Risedronate is also used to treat Paget's disease of bone. Risedronate may also be used for purposes not listed in this medication guide.

?

Disclaimer: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).